Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Receivables (2016 - 2025)

Amicus Therapeutics filings provide 14 years of Receivables readings, the most recent being $115.3 million for Q4 2025.

  • On a quarterly basis, Receivables rose 14.05% to $115.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $115.3 million, a 14.05% increase, with the full-year FY2025 number at $115.3 million, up 14.05% from a year prior.
  • Receivables hit $115.3 million in Q4 2025 for Amicus Therapeutics, up from $113.8 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $115.3 million in Q4 2025 to a low of $44.9 million in Q1 2021.
  • Median Receivables over the past 5 years was $70.8 million (2023), compared with a mean of $74.9 million.
  • Biggest five-year swings in Receivables: grew 1.7% in 2022 and later surged 40.2% in 2023.
  • Amicus Therapeutics' Receivables stood at $52.7 million in 2021, then grew by 25.68% to $66.2 million in 2022, then skyrocketed by 32.38% to $87.6 million in 2023, then increased by 15.37% to $101.1 million in 2024, then rose by 14.05% to $115.3 million in 2025.
  • The last three reported values for Receivables were $115.3 million (Q4 2025), $113.8 million (Q3 2025), and $105.8 million (Q2 2025) per Business Quant data.